This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rufo-Campos, M. Articles by Martínez-Bermejo, A. Search for Related Content PubMed PubMed Citation Articles by Rufo-Campos, M. Articles by Martínez-Bermejo, A. Social Bookmarking                         What's this?

Long-Term Use of Oxcarbazepine Oral Suspension in Childhood Epilepsy: Open-Label Study

Pediatric Neurology Service,Virgen del Rocío, Children's University Hospital, Seville, Spain, miguel.rufo{at}telefonica.net

Carlos Casas-Fernández, MD

Pediatric Neurology Service, Virgen de la Arrixaca University Hospital, Murcia, Spain

Antonio Martínez-Bermejo, MD

Pediatric Neurology Service, La Paz University Hospital, Madrid, Spain

Studies designed specifically for the pediatric population are needed to assess the tolerability and safety of the new antiepileptic drugs. The purpose of this study was to document the safety, ease of dosing, and acceptance of oxcarbazepine oral suspension in pediatric patients in monotherapy and polytherapy. A prospective, multicenter, open-label study was conducted at the neurology services of three pediatric university hospitals over 12 months. After obtaining signed informed consent, we enrolled a series of 62 patients with epilepsy aged between 2 months and 14 years who began oxcarbazepine treatment in monotherapy or in combination with other antiepileptic drugs to assess the seizure frequency, safety (adverse events), and acceptance of the pharmaceutical form by the patient's family. Fifty patients (80.6%) reduced seizures by at least 50%, 44 (71%) saw a reduction in seizure frequency of over 75%, and 29 (46.8%) were seizure free at the end of the study. The difference in the number of seizures before and after the study was statistically significant, both overall and by type of pathology. Adverse events occurred in four patients (6.4%) and required withdrawal of the drug in two cases (skin rash); three patients (4.8%) withdrew for inefficacy. Five patients (8.1%) withdrew from the treatment. We concluded that, in this series of patients, oxcarbazepine in oral suspension form was seen to help reduce seizure frequency, to have few side effects, and to be accepted by parents and patients. (J Child Neurol 2006;21:480—485; DOI 10.2310/7010.2006.00120).

Journal of Child Neurology, Vol. 21, No. 6, 480-485 (2006)
DOI: 10.1177/08830738060210061701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?